Home LiteratureArticle Details
PMID: 17090560 Published · ppublish English Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.

BMJ (Clinical research ed.) ·Vol. 333 ·No. 7580 ·2006-12-09 ·Pages 1193

Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, Kramer MH, Prins JM, Slee PH, Kaasjager K, Hoepelman AI

Abstract

To compare the effectiveness of an early switch to oral antibiotics with the standard 7 day course of intravenous antibiotics in severe community acquired pneumonia. Multicentre randomised controlled trial. Five teaching hospitals and 2 university medical centres in the Netherlands. 302 patients in non-intensive care wards with severe community acquired pneumonia. 265 patients fulfilled the study requirements. Three days of treatment with intravenous antibiotics followed, when clinically stable, by oral antibiotics or by 7 days of intravenous antibiotics. Clinical cure and length of hospital stay. 302 patients were randomised (mean age 69.5 (standard deviation 14.0), mean pneumonia severity score 112.7 (26.0)). 37 patients were excluded from analysis because of early dropout before day 3, leaving 265 patients for intention to treat analysis. Mortality at day 28 was 4% in the intervention group and 6% in the control group (mean difference 2%, 95% confidence interval -3% to 8%). Clinical cure was 83% in the intervention group and 85% in the control group (2%, -7% to 10%). Duration of intravenous treatment and length of hospital stay were reduced in the intervention group, with mean differences of 3.4 days (3.6 (1.5) v 7.0 (2.0) days; 2.8 to 3.9) and 1.9 days (9.6 (5.0) v 11.5 (4.9) days; 0.6 to 3.2), respectively. Early switch from intravenous to oral antibiotics in patients with severe community acquired pneumonia is safe and decreases length of hospital stay by 2 days. Clinical Trials NCT00273676 [ClinicalTrials.gov].

MeSH Terms
Administration, Oral Adolescent Adult Aged Amoxicillin/therapeutic use Anti-Bacterial Agents/administration & dosage Cephalosporins/therapeutic use Clavulanic Acid/therapeutic use Community-Acquired Infections/drug therapy Drug Combinations Humans Infusions, Intravenous Middle Aged Pneumonia, Bacterial/drug therapy Time Factors Treatment Outcome
Chemicals
Anti-Bacterial Agents Cephalosporins Drug Combinations Clavulanic Acid Amoxicillin
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Oosterheert Jan Jelrik
Department of Internal Medicine and Infectious Diseases, University Medical Centre, PO Box 85500, 3508 GA Utrecht, Netherlands.
Bonten Marc J M
Schneider Margriet M E
Buskens Erik
Lammers Jan-Willem J
Hustinx Willem M N
Kramer Mark H H
Prins Jan M
Slee Peter H Th J
Kaasjager Karin
Hoepelman Andy I M
References (21)
21 references, click to expand
  1. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.
    Arch Intern Med. 1999 Nov 8;159(20):2449-54 PMID: 10665893
  2. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.
    Arch Intern Med. 1997 Aug 11-25;157(15):1709-18 PMID: 9250232
  3. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
    JAMA. 2000 Feb 9;283(6):749-55 PMID: 10683053
  4. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia.
    Arch Intern Med. 2001 Mar 26;161(6):848-50 PMID: 11268227
  5. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.
    Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54 PMID: 11401897
  6. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.
    Am J Med. 2001 Oct 1;111(5):367-74 PMID: 11583639
  7. Achieving a safe and early discharge for patients with community-acquired pneumonia.
    Med Clin North Am. 2001 Nov;85(6):1427-40 PMID: 11686189
  8. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia.
    Arch Intern Med. 2002 Jun 10;162(11):1278-84 PMID: 12038946
  9. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia.
    Clin Ther. 2004 Feb;26(2):294-303 PMID: 15038952
  10. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration.
    Clin Infect Dis. 1992 Nov;15 Suppl 1:S62-88 PMID: 1477253
  11. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures.
    Clin Infect Dis. 1993 Aug;17 Suppl 1:S79-82 PMID: 8399943
  12. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.
    Arch Intern Med. 1995 Jun 26;155(12):1273-6 PMID: 7778957
  13. Evaluation of a pneumonia practice guideline in an interventional trial.
    Am J Respir Crit Care Med. 1996 Mar;153(3):1110-5 PMID: 8630553
  14. Trends in infectious diseases mortality in the United States.
    JAMA. 1996 Jan 17;275(3):189-93 PMID: 8604170
  15. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy.
    Chest. 1996 Oct;110(4):965-71 PMID: 8874253
  16. A prediction rule to identify low-risk patients with community-acquired pneumonia.
    N Engl J Med. 1997 Jan 23;336(4):243-50 PMID: 8995086
  17. Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
    Eur Respir J. 1997 Jul;10(7):1530-4 PMID: 9230242
  18. Legionellosis.
    N Engl J Med. 1997 Sep 4;337(10):682-7 PMID: 9278466
  19. [Optimization of the antibiotics policy in the Netherlands. II. SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home and as nosocomial infections. The Netherlands Antibiotic Policy Foundation].
    Ned Tijdschr Geneeskd. 1998 Apr 25;142(17):952-6 PMID: 9623168
  20. A prospective, multicenter study of a pneumonia practice guideline.
    Chest. 1998 Jul;114(1):115-9 PMID: 9674457
  21. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis.
    Respir Med. 1998 Aug;92(8):1032-9 PMID: 9893772
Article Info
Journal
BMJ (Clinical research ed.)
Abbr.
BMJ
ISSN
1756-1833
Published
2006-12-09
Epub
2006-00-07
Pages
1193
Language
English
Region
England
NLM ID
8900488
PMCID
PMC1693658
Subset
IM
Databases
ClinicalTrials.gov
NCT00273676
Corrections
CommentIn
ReprintIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]